Forensic Analysis · General / Diversified · as of Aug 11, 2026

Staar Surgical Co (STAA)

A forensic read on Staar Surgical Co built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Safe

Financial health

13.4

Distress distance

Clean

Earnings quality

Forensic signals

-57.6

P / E (ttm)

-23.4%

ROE

$1.3B

Market cap

0.00%

Dividend yield

-23.7%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Staar Surgical Co earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 13.4, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

-31.5%

FY2026

Return on invested capital. Return on invested capital is -31.5% in the latest fiscal year and slipping from 14% — well below its ~9% cost of capital, so reinvested dollars may be destroying value, not building it.

FCF ($40M)

FY2026

Shareholder returns. Returned $6M to shareholders (buybacks + dividends) in FY2026, but free cash flow was ($40M) after capex — there was no free cash flow to fund the payout from at all, and operating cash flow itself was negative or zero that year too. The entire return is coming from debt or cash reserves, not cash the business itself generated — a harder case than returns merely running ahead of free cash flow, since here there was none to run ahead of.

237d

FY2014→FY2015

Inventory days. Days inventory outstanding moved from 197 to 237 FY2014→FY2015 (against cost of goods sold; inventory +1% vs -7% in cost of sales). Inventory is building a little faster than sales — watch for markdowns.

+0.1%/yr

FY2022–FY2026

Share count. Diluted share count changed +0% over the last 4 years to FY2026 (+0.1%/yr). Roughly flat — buybacks ($6M) are about offsetting stock comp ($31M), not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.

Key fundamentals

Latest Revenue$239.4M

Revenue Growth YoY-23.7%

Net Margin-33.6%

Free Cash Flow-$40.0M

Return on Equity-23.4%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Staar Surgical Co's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.